IN2014MN02485A - - Google Patents

Info

Publication number
IN2014MN02485A
IN2014MN02485A IN2485MUN2014A IN2014MN02485A IN 2014MN02485 A IN2014MN02485 A IN 2014MN02485A IN 2485MUN2014 A IN2485MUN2014 A IN 2485MUN2014A IN 2014MN02485 A IN2014MN02485 A IN 2014MN02485A
Authority
IN
India
Prior art keywords
methyl
pentahydroxyhexyl
dihydroquinoline
carboxamide
oxo
Prior art date
Application number
Inventor
Avital Laxer
Konstantin Ulanenko
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2014MN02485A publication Critical patent/IN2014MN02485A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The subject invention provides pharmaceutical compositions Containing laquinimod or a pharmaceutically acceptable salt thereof an isolated compound of N ethyl 4 hydroxyl 1 methyl 5 (methyl (2 3 4 5 6 pentahydroxyhexyl) amino) 2 oxo N phenyl 1 2 dihydroquinoline 3 carboxamide or a salt thereof compositions containing N ethyl 4 hydroxyl 1 methyl 5 (methyl (2 3 4 5 6 pentahydroxyhexyl) amino) 2 oxo N phenyl 1 2 dihydroquinoline 3 carboxamide and methods of preparing the same.
IN2485MUN2014 2012-05-08 2013-05-07 IN2014MN02485A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644054P 2012-05-08 2012-05-08
PCT/US2013/039911 WO2013169746A2 (en) 2012-05-08 2013-05-07 N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide

Publications (1)

Publication Number Publication Date
IN2014MN02485A true IN2014MN02485A (en) 2015-07-17

Family

ID=49551433

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2485MUN2014 IN2014MN02485A (en) 2012-05-08 2013-05-07

Country Status (19)

Country Link
US (1) US8809537B2 (en)
EP (1) EP2697201A4 (en)
KR (1) KR20150022816A (en)
CN (1) CN104395291B (en)
AR (1) AR090975A1 (en)
AU (1) AU2013259779B2 (en)
BR (1) BR112014028121A2 (en)
CA (1) CA2873258A1 (en)
EA (1) EA201492029A1 (en)
HK (1) HK1207080A1 (en)
IL (1) IL235338A0 (en)
IN (1) IN2014MN02485A (en)
MX (1) MX2014013664A (en)
NZ (1) NZ630549A (en)
SG (1) SG11201407447XA (en)
TW (1) TW201350467A (en)
UY (1) UY34791A (en)
WO (1) WO2013169746A2 (en)
ZA (1) ZA201408825B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (en) 2012-02-03 2014-10-08 泰华制药工业有限公司 Use of laquinimod for the treatment of patients with Crohn's disease who have failed first-line anti-TNFα therapy
JP6215238B2 (en) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, its formulation and use
TW201400117A (en) 2012-06-05 2014-01-01 Teva Pharma Treatment of ocular inflammation with laquinimod
TW201410244A (en) 2012-08-13 2014-03-16 Teva Pharma Laquinimod for treatment of GABA mediated disorders
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma Amine salts of laquinimod
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2159804A (en) * 1937-11-23 1939-05-23 Du Pont N-nitroaryl polyhydroxy alkyl amino compounds and process of preparing the same
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4782155A (en) 1986-03-19 1988-11-01 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
SE8902076D0 (en) 1989-06-09 1989-06-09 Pharmacia Ab DERIVATIVES OF QUINOLINE-3-CARBOXANILIDE
US5139878A (en) 1991-08-12 1992-08-18 Allied-Signal Inc. Multilayer film constructions
US6043006A (en) * 1997-09-04 2000-03-28 Fuji Photo Film Co., Ltd. 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method
SE9801474D0 (en) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (en) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (en) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
ES2246238T3 (en) 1999-06-07 2006-02-16 Altana Pharma Ag NEW PREPARATION AND METHOD OF ADMINISTRATION UNDERSTANDING AN INHIBITOR OF THE LABIL PUMPS IN THE MIDDLE ACID.
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (en) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (en) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
NZ567088A (en) 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (en) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 Stable laquinimod preparations
AU2008242703B2 (en) 2007-04-19 2011-08-18 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
KR20110048571A (en) 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 2-oxo-1,2-dihydro-quinoline modulator with immune function
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
UY32427A (en) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
JP2012530701A (en) 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド Treatment of multiple sclerosis with laquinimod
PL2458992T3 (en) 2009-07-30 2016-07-29 Teva Pharma Treatment of crohn's disease with laquinimod
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
CA2791711A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
DK2542079T3 (en) 2010-03-03 2014-08-25 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
SG183512A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
EP2590653A4 (en) 2010-07-09 2014-01-01 Teva Pharma 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
JP2012047974A (en) * 2010-08-26 2012-03-08 Toshiba Corp Image display apparatus and image display method
WO2012050500A1 (en) * 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
AU2011338647A1 (en) 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
IN2014MN00333A (en) 2011-07-28 2015-09-25 Teva Pharma
AU2012286701A1 (en) 2011-07-28 2014-03-06 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
SG11201407447XA (en) 2015-02-27
AU2013259779B2 (en) 2017-06-08
WO2013169746A2 (en) 2013-11-14
EP2697201A4 (en) 2014-11-26
TW201350467A (en) 2013-12-16
BR112014028121A2 (en) 2017-06-27
UY34791A (en) 2013-11-29
CN104395291A (en) 2015-03-04
US8809537B2 (en) 2014-08-19
AR090975A1 (en) 2014-12-17
ZA201408825B (en) 2016-07-27
NZ630549A (en) 2016-01-29
EA201492029A1 (en) 2015-06-30
CA2873258A1 (en) 2013-11-14
HK1207080A1 (en) 2016-01-22
IL235338A0 (en) 2014-12-31
CN104395291B (en) 2017-07-28
WO2013169746A3 (en) 2013-12-05
EP2697201A2 (en) 2014-02-19
US20130345256A1 (en) 2013-12-26
KR20150022816A (en) 2015-03-04
MX2014013664A (en) 2015-04-17
AU2013259779A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
IN2014DN10670A (en)
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
IN2014MN02485A (en)
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EA033689B9 (en) Inhibitors of kras g12c
PH12016501310B1 (en) Pharmaceutical compositions comprising azd9291
MX2015011984A (en) Dihydro-pyrrolopyridinone bromodomain inhibitors.
PL402710A1 (en) Pharmaceutical compositions comprising imatinib or a pharmaceutically acceptable salt thereof and methods for their preparation
MX2016007440A (en) Bromodomain inhibitors.
AU2018297348A1 (en) Compositions for parenteral administration of therapeutic agents
PH12016502246A1 (en) Carboxamide derivatives
MX2016013431A (en) Pharmaceutical compositions comprising antibacterial agents.
EP3103453A4 (en) Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
EP3493808A4 (en) Pharmaceutical compositions of ibrutinib
HK1198296A1 (en) N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
IN2014MU00859A (en)
WO2019004980A3 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
IN2013MU03421A (en)
MX2016005539A (en) Pharmaceutical compositions comprising antibacterial agents.
MX2016013428A (en) Pharmaceutical compositions comprising antibacterial agents.
IN2013MU03309A (en)
MX2018010652A (en) Pharmaceutical compositions.
IN2014MU01194A (en)
HK40052632A (en) Methods and compositions for delivery of agents across the blood-brain barrier
GB2569616B (en) Sustained release oral pharmaceutical compositions of dicycloverine